Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new patient-reported post-hoc data from the KINECT®-HD study highlighting significant reductions in both cognitive and motor-related ...

Chorea can affect various body parts and interfere with motor coordination, gait, swallowing and speech. HD is estimated to affect approximately 41,000 adults in the U.S., ...

Robeco Institutional Asset Management B.V. increased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – ...

Background A 75-year-old woman with rheumatoid arthritis presented with a 4-year history of chorea to a hospital movement disorder clinic. The involuntary movements were initially mild, affecting ...

Bessemer Group Inc. trimmed its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 67.3% in ...

Stanley Druckenmiller made a fortune working alongside billionaire George Soros. Today, Druckenmiller has a net worth of $6.9 ...

SOM3355 (bevantolol hydrochloride) hit its objectives in a phase 2 trial in patients with Huntington's disease, improving the involuntary, jerky movements known as chorea that are a key symptom of ...

Prilenia Therapeutics is planning to file its Huntington’s disease drug pridopidine in the EU shortly, after mixed results in a phase 3 trial.

"The KINECT-HD study demonstrated INGREZZA's ability to significantly reduce chorea, one of the most visible and disruptive symptoms of Huntington's disease, which often occurs alongside cognitive ...

The hallmark symptom of Huntington's disease is the presence of progressive chorea (abnormal involuntary movements), which is accompanied by psychiatric symptoms and cognitive decline. Latest ...

Chorea Thus in patients with Parkinson’s disease levodopa, dopamine agonists, and COMT (catechol-O-methyltransferase) inhibitors may all contribute. About half of Parkinson’s disease patients treated ...

Medical news, education and information for physicians and health care professionals, presented by specialty and topic. From Healio and the Wyanoke Group.